A simple and reliable ultra-high-performance liquid chromatographic (UHPLC) method was developed and validated for determination of tetrahydrocurcumin diglutaric acid (TDG) and applied for evaluation of its bioaccessibility. The analytical method was validated to demonstrate as a stability-indicating assay (SIA) according to the ICH Q2(R1) guidelines under various force degradation conditions including thermal degradation, moisture, acid and base hydrolysis, oxidation, and photolysis. The developed chromatographic condition could completely separate all degradants from the analyte of interest. The method linearity was verified in the range of 0.4-12 μg/mL with the coefficient of determination (r) > 0.995. The accuracy and precision of the method provided %recovery in the range of 98.9-104.2% and %RSD lower than 4.97%, respectively. The limit of detection and quantitation were found to be 0.25 μg/mL and 0.40 μg/mL, respectively. This method has been successfully applied for the bioaccessibility assessment of TDG with the bioaccessibility of TDG approximately four fold greater than THC in simulated gastrointestinal fluid. The validated SIA method can also benefit the quality control of TDG raw materials in pharmaceutical and nutraceutical development.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966976 | PMC |
http://dx.doi.org/10.3390/molecules28041678 | DOI Listing |
Sci Rep
January 2025
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, 11829, Cairo, Egypt.
In recent times, a truly exquisite pharmaceutical marvel has graced the world of medicine, known as Safinamide (SAF). This opulent creation has been specifically tailored to cater to the needs of individuals afflicted with Parkinson's disease (PD), an esteemed neurological condition renowned for its regal ability to impede motor skills, coordination, and equilibrium. It is highly improbable that degradation products of pharmaceutical components would significantly compromise efficiency and safety of a drug during its shelf life.
View Article and Find Full Text PDFJ Sep Sci
January 2025
Department of Pharmacy, Pharmaceutical Sciences Postgraduate Research Program, Universidade Federal do Paraná, Curitiba, Paraná, Brazil.
J AOAC Int
December 2024
J-Star Research, Inc. A Porton Company 6 Cedarbrook Drive, Cranbury Township, NJ 08512, USA.
Background: Moxidectin is an active pharmaceutical ingredient (API) extensively used in various drug products within the pharmaceutical and animal health sectors. Despite its widespread use, the analytical methods prescribed by the United States Pharmacopeia (USP) and European Pharmacopoeia (EP, Ph. Eur.
View Article and Find Full Text PDFBiosens Bioelectron
March 2025
Center of Advanced Analysis and Gene Sequencing, Key Laboratory of Molecular Sensing and Harmful Substances Detection Technology, Zhengzhou University, Kexue Avenue 100, Zhengzhou, Henan, 450001, PR China.
Both minimal change disease (MCD) and focal segmental glomerular sclerosis (FSGS) are the pathological types of primary nephrotic syndrome (PNS) and cannot be readily distinguished owing to their highly similar clinical presentations. Currently, methods for clinical MCD and FSGS diagnosis still rely on invasive renal biopsy which impede rapid and accurate diagnosis for timely treatment management. In this study, a novel diagnostic strategy by introducing the dyes with spironolactone structure into the metal-organic cage to construct three dye@MOCs composites has been developed and employed as fluorescence sensor array for assisting in the auxiliary differential diagnosis of MCD and FSGS based on the distinguishable biothiols in urine.
View Article and Find Full Text PDFJ Pediatr Pharmacol Ther
December 2024
Research and Development (KI, MC), PCCA, Houston, TX.
Objective: In the United States, ursodiol is commercially available as solid dosage forms, which represents a problem for children who cannot swallow capsules or tablets. There is a lack of an age-appropriate formulation for ursodiol, and the extemporaneous preparation of an oral suspension with an extended beyond-use-date (BUD) may represent a good therapeutic alternative for the pediatric population. However, all pharmacists need validated stability studies to prepare oral liquids with high quality and safety.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!